Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 6609 · Pharmacists Fight Back in Medicare and Medicaid Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1320a–7a Civil monetary penalties

+4 −2Shown
More for 42 U.S.C. § 1320a–7a
Read § 1320a–7aOnly this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    in paragraph (10), by adding or at the end;

  2. Carried out:

    by inserting after paragraph (10) the following new paragraph:(11) commits an act described in section 1128B(i);; and

  3. Carried out:

    by striking or in cases under paragraph (9) and inserting in cases under paragraph (9); and

  4. Carried out:

    by striking fact) and inserting fact, or in cases under paragraph (11), $1,000,000 for each such act).

§ 1320a–7a(a)–(b)

Start of § 1320a–7a to (a)(8) unchanged ·

(9) 4 knowingly makes or causes to be made any false statement, omission, or misrepresentation of a material fact in any application, bid, or contract to participate or enroll as a provider of services or a supplier under a Federal health care program (as so defined), including Medicare Advantage organizations under part C of subchapter XVIII, prescription drug plan sponsors under part D of subchapter XVIII, medicaid managed care organizations under subchapter XIX, and entities that apply to participate as providers of services or suppliers in such managed care organizations and such plans;5

(10) knows of an overpayment (as defined in paragraph (4) of section 1320a–7k(d) of this title) and does not report and return the overpayment in accordance with such section;[inserted: or]

(11) [inserted: commits an act described in section 1128B(i);]

shall be subject, in addition to any other penalties that may be prescribed by law, to a civil money penalty of not more than $20,000 for each item or service (or, in cases under paragraph (3), $30,000 for each individual with respect to whom false or misleading information was given; in cases under paragraph (4), $20,000 for each day the prohibited relationship occurs; in cases under paragraph (7), $100,000 for each such act, in cases under paragraph (8), $100,000 for each false record or statement, or 3 in cases under paragraph (9), $15,000 for each day of the failure described in such paragraph); [struck: or ]in cases under paragraph (9), $100,000 for each false statement or misrepresentation of a material fact[inserted: , or in cases under paragraph (11])[inserted: , $1,000,000 for each such act)]. In addition, such a person shall be subject to an assessment of not more than 3 times the amount claimed for each such item or service in lieu of damages sustained by the United States or a State agency because of such claim (or, in cases under paragraph (7), damages of not more than 3 times the total amount of remuneration offered, paid, solicited, or received, without regard to whether a portion of such remuneration was offered, paid, solicited, or received for a lawful purpose; or in cases under paragraph (9), an assessment of not more than 3 times the total amount claimed for each item or service for which payment was made based upon the application containing the false statement or misrepresentation of a material fact). In addition the Secretary may make a determination in the same proceeding to exclude the person from participation in the Federal health care programs (as defined in section 1320a–7b(f)(1) of this title) and to direct the appropriate State agency to exclude the person from participation in any State health care program.

(b) Payments to induce reduction or limitation of services

(1) If a hospital or a critical access hospital knowingly makes a payment, directly or indirectly, to a physician as an inducement to reduce or limit medically necessary services provided with respect to individuals who—

Rest of § 1320a–7a unchanged ·

42 U.S.C. § 1320a–7b Criminal penalties for acts involving Federal health care programs

+9 −0Shown
More for 42 U.S.C. § 1320a–7b
Read § 1320a–7bOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1128B of the Social Security Act (42 U.S.C. 1320a–7b) is amended by adding at the end the following new subsection:(i) Whoever provides pharmacy benefits management services on behalf of a prescription drug plan sponsor under part D of title XVIII or a medicaid managed care organization under title XIX and— (1) knowingly and willfully fails to comply with the pharmacy payment requirements …

§ 1320a–7b(g)–(i)

Start of § 1320a–7b to (f)(2) unchanged ·

(g) Liability under subchapter III of chapter 37 of title 31 In addition to the penalties provided for in this section or section 1320a–7a of this title, a claim that includes items or services resulting from a violation of this section constitutes a false or fraudulent claim for purposes of subchapter III of chapter 37 of title 31.

(h) Actual knowledge or specific intent not required With respect to violations of this section, a person need not have actual knowledge of this section or specific intent to commit a violation of this section.

(i) [inserted: Whoever provides pharmacy benefits management services on behalf of a prescription drug plan sponsor under part D of title XVIII or a medicaid managed care organization under title XIX and—]

(1) [inserted: knowingly and willfully fails to comply with the pharmacy payment requirements under section 1860D–12(h)(2) or section 1927(e)(6)(A), as applicable;]

(2) [inserted: knowingly and willfully engages in steering (as defined in section 1860D–12(h)); or]

(3) [inserted: knowingly and willfully fails to comply with the rebate pass-through requirements under section 1860D–12(h)(3) or section 1927(e)(6)(C), as applicable,]

[inserted: shall be guilty of a felony and upon conviction thereof shall be fined not more than $1,000,000, or imprisoned for not more than 10 years, or both.]

42 U.S.C. § 1395w–27 Contracts with Medicare+Choice organizations

+2 −0Shown
More for 42 U.S.C. § 1395w–27
Read § 1395w–27Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1857(f)(3) of the Social Security Act (42 U.S.C. 1395w–27(f)(3)) is amended by adding at the end the following new subparagraph:(F) Requirements relating to pharmacy benefit managers.— For plan years beginning on or after January 1, 2027, section 1860D–12(h)..

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 1395w–27(f)–(g)

Start of § 1395w–27 to (f)(3)(E) unchanged ·

(F) Accountability of pharmacy benefit managers for violations of reasonable and relevant contract terms For plan years beginning on or after January 1, 2029, section 1395w–112(b)(9) of this title.

(G) Requirements relating to pharmacy benefit managers For plan years beginning on or after January 1, 2028, section 1395w–112(h) of this title.

(F) [inserted: Requirements relating to pharmacy benefit managers.—] [inserted: For plan years beginning on or after January 1, 2027, section 1860D–12(h).]

(g) Intermediate sanctions

(1) In general If the Secretary determines that a Medicare+Choice organization with a contract under this section—

Rest of § 1395w–27 unchanged ·

42 U.S.C. § 1395w–111 PDP regions; submission of bids; plan approval

+5 −3Shown
More for 42 U.S.C. § 1395w–111
Read § 1395w–111Only this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    in clause (iii), by striking and at the end;

  2. Carried out:

    by redesignating clause (iv) as clause (v); and

  3. Carried out:

    by inserting after clause (iii) the following new clause:(iv) with respect to bids beginning with plan year 2027, assumptions regarding any rebate remittance payments provided under section 1860D–12(h)(3)(B), subtracted from the actuarial value to produce such bid; and.

§ 1395w–111(b)(2)Information described(C)–(E)

Start of § 1395w–111 to (b)(2)(C)(i) unchanged ·

(ii) the portion of such bid attributable to basic prescription drug coverage and, if applicable, the portion of such bid attributable to supplemental benefits;

(iii) assumptions regarding the reinsurance subsidy payments provided under section 1395w–115(b) of this title subtracted from the actuarial value to produce such bid;[struck: and]

(iv) [inserted: with respect to bids beginning with plan year 2027, assumptions regarding any rebate remittance payments provided under section 1860D–12(h)(3)(B), subtracted from the actuarial value to produce such bid; and]

[struck: (iv)] [inserted: (v)] administrative expenses assumed in the bid.

(D) Service area The service area for the plan.

(E) Level of risk assumed

Rest of § 1395w–111 unchanged ·

42 U.S.C. § 1395w–112 Requirements for and contracts with prescription drug plan (PDP) sponsors

+96 −0Shown
More for 42 U.S.C. § 1395w–112
Read § 1395w–112Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1860D–12 of the Social Security Act (42 U.S.C. 1395w–112) is amended by adding at the end the following new subsection:(h) Requirements relating to pharmacy benefit managers.— For plan years beginning on or after January 1, 2027: (1) In general.— Each contract entered into with a PDP sponsor under this part with respect to a prescription drug plan offered by such sponsor shall provide— (A) that …

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 1395w–112(h)–(h)

Start of § 1395w–112 to (h)(7)(B)(iii) unchanged ·

(iv) any other amounts or methodologies prohibited by the Secretary.

(C) Pharmacy benefit manager The term “pharmacy benefit manager” means any person or entity that, either directly or through an intermediary, acts as a price negotiator or group purchaser on behalf of a PDP sponsor or prescription drug plan, or manages the prescription drug benefits provided by such sponsor or plan, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies, controlling the cost of covered part D drugs, or the provision of related services. Such term includes any person or entity that carries out one or more of the activities described in the preceding sentence, irrespective of whether such person or entity calls itself a “pharmacy benefit manager”.

(h) [inserted: Requirements relating to pharmacy benefit managers.—] [inserted: For plan years beginning on or after January 1, 2027:]

(1) [inserted: In general.—] [inserted: Each contract entered into with a PDP sponsor under this part with respect to a prescription drug plan offered by such sponsor shall provide—]

(A) [inserted: that the sponsor (and any pharmacy benefit manager acting on behalf of such sponsor, including any affiliate of such PBM, as applicable)—]

(i) [inserted: shall comply with the pharmacy payment requirements described in paragraph (2);]

(ii) [inserted: shall comply with the rebate pass-through requirements described in paragraph (3);]

(iii) [inserted: shall comply with the reporting requirement described in paragraph (4); and]

(iv) [inserted: may not engage in steering; and]

(B) [inserted: that any pharmacy benefit manager acting on behalf of such sponsor has a written agreement with the PDP sponsor under which the PBM, and any affiliate of such PBM, as applicable, agrees to meet the requirements described in subparagraph (A).]

(2) [inserted: Pharmacy payment requirements.—] [inserted: For purposes of paragraph (1)(A)(i), the pharmacy payment requirements described in this paragraph are, with respect to a PDP sponsor (and a PBM acting on behalf of such sponsor, including any affiliate of such PBM, as applicable) the following:]

(A) [inserted: The sponsor, PBM, or affiliate reimburses an in-network pharmacy for the ingredient cost of a covered part D drug in an amount equal to the sum of—]

(i) [inserted: the national average drug acquisition cost for the drug as of the day that the pharmacy submits a claim for payment for such drug (as determined based upon the retail survey prices obtained under section 1927(f)(1)), or, in the case of a drug for which no such national average drug acquisition cost is available, the wholesale acquisition cost for such drug as of such day; and]

(ii) [inserted: an amount equal to 4 percent of the amount described in clause (i), or $50, whichever is less.]

(B) [inserted: With respect to each covered part D drug obtained from an in-network pharmacy by an individual enrolled in the prescription drug plan, the sponsor, PBM, or affiliate—]

(i) [inserted: pays such pharmacy a dispensing fee that is equal to the dispensing fee paid for such drug under the State plan under title XIX in the State in which such pharmacy is located, as reported by the State under section 1927(f)(2); and]

(ii) [inserted: does not require such individual to reimburse such dispensing fee or otherwise increase the amount owed by such individual with respect to such drug to account for such dispensing fee.]

(C) [inserted: The sponsor, PBM, or affiliate does not impose any fee or other payment requirement upon an in-network pharmacy that would have the effect of reducing the amount received by the pharmacy under the other provisions of this paragraph.]

(3) [inserted: Rebate pass-through requirements.—] [inserted: For purposes of paragraph (1)(A)(ii), the rebate pass-through requirements described in this paragraph are, with respect to a PDP sponsor (and a PBM acting on behalf of such sponsor, including any affiliate of such PBM, as applicable), that, in the case that such sponsor, PBM, or affiliate receives a manufacturer rebate in connection with a covered part D drug—]

(A) [inserted: in the case that such drug is obtained from an in-network pharmacy by an individual enrolled in the prescription drug plan, the PDP sponsor, PBM, or affiliate applies, at the point of sale of such drug, a reduction to the amount of any coinsurance or copayment owed by such individual with respect to such drug, such that the amount of coinsurance or copayment so owed is calculated based on an amount equal to the reimbursement amount for such drug determined under paragraph (2)(A), less the amount of such rebate (or, in the case of a rebate described in paragraph (5)(B)(ii), the amount of such rebate that is attributable to such drug and such individual); and]

(B) [inserted: in the case that the entity receiving the manufacturer rebate in connection with such drug is a PBM (or any affiliate of such PBM), the PBM (or affiliate) remits to the PDP sponsor an amount (in this subparagraph referred to as the “rebate remittance payment”) equal to the amount of such rebate (or, in the case of a rebate described in paragraph (5)(B)(ii), the amount of such rebate that is attributable to such drug and such individual), less the amount by which the coinsurance or copayment owed by an individual enrolled in the prescription drug plan with respect to such drug was reduced pursuant to subparagraph (A); and]

(C) [inserted: in the case that such drug is obtained from an in-network pharmacy by an individual enrolled in the prescription drug plan who is a subsidy eligible individual (as defined in section 1860D–14(a)(3)), the PDP sponsor remits to the Secretary, at such time and in such manner as the Secretary may specify—]

(i) [inserted: in the case that the entity receiving the manufacturer rebate in connection with such drug is a PBM (or any affiliate of such PBM), the amount received by the sponsor under subparagraph (B) with respect to such drug and such individual; and]

(ii) [inserted: in the case that the entity receiving the manufacturer rebate in connection with such drug is the PDP sponsor, an amount equal to the amount of such rebate (or, in the case of a rebate described in paragraph (5)(B)(ii), the amount of such rebate that is attributable to such drug and such individual), less the amount by which the coinsurance or copayment owed by such individual with respect to such drug was reduced pursuant to subparagraph (A).]

(4) [inserted: Reporting requirement.—] [inserted: For purposes of paragraph (1)(A)(iii), the reporting requirement described in this paragraph is, with respect to a PBM and any affiliate of such PBM, that, not later than July 1, 2028, and not less frequently than annually thereafter, the PBM (or affiliate) submits to the PDP sponsor and to the Secretary a report containing a certification that, during the preceding year, such PBM (or affiliate)—]

(A) [inserted: complied with the requirements under paragraphs (2) and (3); and]

(B) [inserted: did not engage in steering.]

(5) [inserted: Definitions.—] [inserted: For purposes of this subsection:]

(A) [inserted: Affiliate.—] [inserted: The term “affiliate” means, with respect to a PBM or PDP sponsor, an entity that, directly or indirectly—]

(i) [inserted: owns, controls, or has an investment interest in such PBM or PDP sponsor;]

(ii) [inserted: is owned by such PBM or PDP sponsor or controlled by such PBM or PDP sponsor;]

(iii) [inserted: that such PBM or PDP sponsor has an investment interest in; or]

(iv) [inserted: is under common ownership or corporate control of such PBM or PDP sponsor.]

(B) [inserted: Manufacturer rebate.—] [inserted: The term “manufacturer rebate”—]

(i) [inserted: means any price concession (including any payment, discount, administration fee, credit, incentive, or penalty) provided by the manufacturer of a covered part D drug (or any affiliate, subsidiary, third party, or intermediary of such manufacturer) to a PDP sponsor (or any PBM acting on behalf of such sponsor, including any affiliate of such PBM, as applicable), in connection with the furnishing of such covered part D drug to an individual enrolled in a prescription drug plan offered by such sponsor; and]

(ii) [inserted: includes any such price concession that is determined based upon—]

(I) [inserted: the aggregate volume of such covered part D drug (or a group of covered part D drugs that includes such part D drug) furnished to individuals enrolled in a prescription drug plan offered by such sponsor; or]

(II) [inserted: the furnishing of any service provided to the manufacturer by such sponsor (or any PBM acting on behalf of such sponsor, or any affiliate of such PBM (including an off-shore entity or group purchasing organization), as applicable) in connection with the furnishing of such covered part D drug (or a group of covered part D drugs that includes such part D drug).]

(C) [inserted: Pharmacy benefit manager; PBM.—] [inserted: The terms “pharmacy benefit manager” and “PBM” mean a person, business entity, affiliate, or other entity that performs pharmacy benefits management services.]

(D) [inserted: Pharmacy benefits management services.—] [inserted: The term “pharmacy benefits management services”—]

(i) [inserted: means the managing or administration of a plan or program that pays for, reimburses, and covers the cost of prescription drugs and medical devices; and]

(ii) [inserted: includes the processing and payment of claims for prescription drugs and the adjudication of appeals or grievances related to qualified prescription drug coverage under this part.]

(E) [inserted: Steering.—] [inserted: The term “steering” means, with respect to a PDP sponsor (and any PBM acting on behalf of such sponsor, including any affiliate of such PBM, as applicable)—]

(i) [inserted: directing, ordering, or requiring an enrollee in a prescription drug plan to use a specific pharmacy, including an affiliate pharmacy, for the purpose of filling a prescription for a covered part D drug or receiving services from a pharmacist;]

(ii) [inserted: offering or implementing a prescription drug plan design that—]

(I) [inserted: requires an enrollee in a prescription drug plan to utilize a pharmacy, including an affiliate pharmacy; or]

(II) [inserted: increases costs to the PDP sponsor or an enrollee, including by requiring an enrollee to pay the full cost for a covered part D drug when such enrollee chooses not to use an affiliate pharmacy;]

(iii) [inserted: advertising, marketing, or promoting a pharmacy, including an affiliate pharmacy, in a manner that encourages enrollees to choose such pharmacy over another in-network pharmacy;]

(iv) [inserted: creating more than one network of pharmacies with respect to a prescription drug plan such that an in-network pharmacy belonging to a specific network (such as a preferred pharmacy network, narrow pharmacy network, or specialty pharmacy network) receives preferential treatment, or engaging in any practice (including accreditation or credentialing standards, day supply limitations, or delivery method limitations) that has the effect of excluding an in-network pharmacy from participation in the network of the PDP sponsor or restricting an in-network pharmacy from filling a prescription for a covered part D drug; or]

(v) [inserted: engaging in any practice that attempts to influence or induce a manufacturer of a covered part D drug to limit the distribution of such drug to a small number of pharmacies or certain types of pharmacies, or to restrict distribution of such drug to non-affiliate pharmacies.]

42 U.S.C. § 1396b Payment to States

+3 −1Shown
More for 42 U.S.C. § 1396b
Read § 1396bOnly this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    by striking and (III) and inserting (III);

  2. Carried out:

    by inserting before the period at the end the following: , and (IV) if the contract includes provisions making the entity responsible for coverage of covered outpatient drugs, the entity shall comply with the requirements of section 1927(e)(6); and

  3. Carried out:

    by adding at the end the following new paragraph:(10) No payment shall be made under this title to a State with respect to expenditures incurred by the State for payment for services provided by an other specified entity (as defined in paragraph (9)(D)(iii)) unless such services are provided in accordance with a contract …

§ 1396b(m)(2)(A)–(B)

Start of § 1396b to (m)(2)(A)(xi) unchanged ·

(xii) such contract, and the entity complies with the applicable requirements of section 1396u–2 of this title; and

(xiii) such contract provides that (I) covered outpatient drugs dispensed to individuals eligible for medical assistance who are enrolled with the entity shall be subject to the same rebate required by the agreement entered into under section 1396r–8 of this title as the State is subject to and that the State shall collect such rebates from manufacturers, (II) capitation rates paid to the entity shall be based on actual cost experience related to rebates and subject to the Federal regulations requiring actuarially sound rates, [struck: and ](III) the entity shall report to the State, on such timely and periodic basis as specified by the Secretary in order to include in the information submitted by the State to a manufacturer and the Secretary under section 1396r–8(b)(2)(A) of this title, information on the total number of units of each dosage form and strength and package size by National Drug Code of each covered outpatient drug dispensed to individuals eligible for medical assistance who are enrolled with the entity and for which the entity is responsible for coverage of such drug under this subsection (other than covered outpatient drugs that under subsection (j)(1) of section 1396r–8 of this title are not subject to the requirements of that section) and such other data as the Secretary determines necessary to carry out this subsection[inserted: , and (IV) if the contract includes provisions making the entity responsible for coverage of covered outpatient drugs, the entity shall comply with the requirements of section 1927(e)(6)].

(B) Subparagraph (A)8 except with respect to clause (ix) of subparagraph (A), does not apply with respect to payments under this subchapter to a State with respect to expenditures incurred by it for payment for services provided by an entity which—

(i)

§ 1396b(m)–(o)

(m)(2)(B)(i)(I)–(9)(D)(iii) unchanged ·

(I) a prepaid inpatient health plan, as defined in section 438.2 of title 42, Code of Federal Regulations (or any successor regulation); and

(II) a prepaid ambulatory health plan, as defined in such section (or any successor regulation).

(10) [inserted: No payment shall be made under this title to a State with respect to expenditures incurred by the State for payment for services provided by an other specified entity (as defined in paragraph (9)(D)(iii)) unless such services are provided in accordance with a contract between the State and such entity which satisfies the requirements of paragraph (2)(A)(xiii).]

(n) Repealed. Pub. L. 100–93, § 8(h)(1), Aug. 18, 1987, 101 Stat. 694

(o) Restrictions on authorized payments to States Notwithstanding the preceding provisions of this section, no payment shall be made to a State under the preceding provisions of this section for expenditures for medical assistance provided for an individual under its State plan approved under this subchapter to the extent that a private insurer (as defined by the Secretary by regulation and including a group health plan (as defined in section 1167(1) of title 29), a service benefit plan, and a health maintenance organization) would have been obligated to provide such assistance but for a provision of its insurance contract which has the effect of limiting or excluding such obligation because the individual is eligible for or is provided medical assistance under the plan.

Rest of § 1396b unchanged ·

42 U.S.C. § 1396r–8 Payment for covered outpatient drugs

+42 −610 of 11 shown
More for 42 U.S.C. § 1396r–8
Read § 1396r–8Only this section
11 changes the bill asks for here, 10 carried out
  1. Carried out:

    in subsection (e), by adding at the end the following new paragraph:(6) Requirements related to pharmacy benefit managers.— A contract between the State and a pharmacy benefit manager, or a contract between the State and a managed care entity or other specified entity (as such terms are defined in section 1903(m)(9)(D) and collectively referred …

  2. Carried out:

    in subsection (k), by adding at the end the following new paragraphs:(13) Pharmacy benefit manager; PBM.— The terms “pharmacy benefit manager” and “PBM” have the meaning given such terms in section 1860D–12(h)(C). (14) Steering.— The term “steering” has the meaning given such term in section 1860D–12(h)(E), except that any reference in such …

  3. Carried out:

    in the subsection heading, by striking retail and inserting covered outpatient drug; and

  4. Carried out:

    in the paragraph heading, by striking retail and inserting covered outpatient drug;

  5. Carried out:

    in subparagraph (A)(i), by striking retail community pharmacy and inserting pharmacy that dispenses covered outpatient drugs, including a retail community pharmacy, mail-order pharmacy, specialty pharmacy, nursing home pharmacy, long-term care facility pharmacy, hospital pharmacy, or clinic pharmacy (but not including a charitable pharmacy or a not-for-profit pharmacy);

  6. Carried out:

    by striking retail; and

  7. Carried out:

    by striking prescription and inserting covered outpatient; and

  8. Carried out:

    in clause (ii), by striking retail community;

  9. Carried out:

    in subparagraph (D)(ii), by striking retail;

  10. Not carried out:

    in subparagraph (E), by striking the term retail each place it appears; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking the term retail each place it appears; and
  11. Carried out:

    by adding at the end the following new subparagraphs:(F) Survey reporting.— In order to meet the requirement of section 1902(a)(54), a State shall require that any pharmacy in the State that receives any payment, reimbursement, administrative fee, discount, rebate, or other price concession related to the dispensing of a covered …

§ 1396r–8(e)–(f)

Start of § 1396r–8 to (e)(3) unchanged ·

[(4) ]6 Establishment of upper payment limits Subject to paragraph (5), the Secretary shall establish a Federal upper reimbursement limit for each multiple source drug for which the FDA has rated three or more products therapeutically and pharmaceutically equivalent, regardless of whether all such additional formulations are rated as such and shall use only such formulations when determining any such upper limit.

(5) Use of amp in upper payment limits The Secretary shall calculate the Federal upper reimbursement limit established under paragraph (4) as no less than 175 percent of the weighted average (determined on the basis of utilization) of the most recently reported monthly average manufacturer prices for pharmaceutically and therapeutically equivalent multiple source drug products that are available for purchase by retail community pharmacies on a nationwide basis. The Secretary shall implement a smoothing process for average manufacturer prices. Such process shall be similar to the smoothing process used in determining the average sales price of a drug or biological under section 1395w–3a of this title.

(6) [inserted: Requirements related to pharmacy benefit managers.—] [inserted: A contract between the State and a pharmacy benefit manager, or a contract between the State and a managed care entity or other specified entity (as such terms are defined in section 1903(m)(9)(D) and collectively referred to in this paragraph as the “entity”) that includes provisions making the entity responsible for coverage of covered outpatient drugs dispensed to individuals enrolled with the entity, shall require—]

(A) [inserted: that the entity or PBM (as applicable) does not engage in steering;]

(B) [inserted: that any payment made by the entity or the PBM (as applicable) for such a drug and related administrative services (as applicable), including payments made by a PBM on behalf of the State or entity, is equal to—]

(i) [inserted: the ingredient cost of such drug, which shall be in an amount equal to the sum of—]

(I) [inserted: the national average drug acquisition cost for the drug as of the day that the pharmacy submits a claim for payment for such drug (as determined based upon the retail survey prices obtained under subsection (f)(1)), or, in the case of a drug for which no such national average drug acquisition cost is available, the wholesale acquisition cost for such drug as of such day; and]

(II) [inserted: an amount equal to 4 percent of the amount described in item (aa), or $50, whichever is less; and]

(ii) [inserted: a dispensing fee that is equal to the dispensing fee paid for such drug under the State plan under this title in the State in which such pharmacy is located, as reported by the State under subsection (f)(2); and]

(C) [inserted: that, in the case that the entity or PBM (as applicable) receives from a manufacturer of a covered outpatient drug a rebate or discount in connection with the furnishing of such drug to an individual enrolled under the State plan (or waiver of such plan), the entity or PBM remits to the State an amount equal to the amount of such rebate.]

(f) Survey of [struck: retail][inserted: covered] [inserted: outpatient drug ]prices; State payment and utilization rates; and performance rankings

(1) Survey of [struck: retail][inserted: covered] [inserted: outpatient drug ]prices

(A) Use of vendor The Secretary may contract services for—

(i) with respect to a [inserted: pharmacy that dispenses covered outpatient drugs, including a ]retail community pharmacy, [inserted: mail-order pharmacy, specialty pharmacy, nursing home pharmacy, long-term care facility pharmacy, hospital pharmacy, or clinic pharmacy (but not including a charitable pharmacy or a not-for-profit pharmacy), ]the determination on a monthly basis of retail survey prices for covered outpatient drugs that represent a nationwide average of consumer purchase prices for such drugs, net of all discounts and rebates (to the extent any information with respect to such discounts and rebates is available); and

(ii) the notification of the Secretary when a drug product that is therapeutically and pharmaceutically equivalent and bioequivalent becomes generally available.

(B) Secretary response to notification of availability of multiple source products If contractor notifies the Secretary under subparagraph (A)(ii) that a drug product described in such subparagraph has become generally available, the Secretary shall make a determination, within 7 days after receiving such notification, as to whether the product is now described in subsection (e)(4).4

(C) Use of competitive bidding In contracting for such services, the Secretary shall competitively bid for an outside vendor that has a demonstrated history in—

(i) surveying and determining, on a representative nationwide basis, [struck: retail ]prices for ingredient costs of [struck: prescription][inserted: covered] [inserted: outpatient ]drugs;

(ii) working with [struck: retail community ]pharmacies, commercial payers, and States in obtaining and disseminating such price information; and

(iii) collecting and reporting such price information on at least a monthly basis.

In contracting for such services, the Secretary may waive such provisions of the Federal Acquisition Regulation as are necessary for the efficient implementation of this subsection, other than provisions relating to confidentiality of information and such other provisions as the Secretary determines appropriate.

(D) Additional provisions A contract with a vendor under this paragraph shall include such terms and conditions as the Secretary shall specify, including the following:

(i) The vendor must monitor the marketplace and report to the Secretary each time there is a new covered outpatient drug generally available.

(ii) The vendor must update the Secretary no less often than monthly on the [struck: retail ]survey prices for covered outpatient drugs.

(iii) The contract shall be effective for a term of 2 years.

(E) Availability of information to States Information on retail survey prices obtained under this paragraph, including applicable information on single source drugs, shall be provided to States on at least a monthly basis. The Secretary shall devise and implement a means for providing access to each State agency designated under section 1396a(a)(5) of this title with responsibility for the administration or supervision of the administration of the State plan under this subchapter of the retail survey price determined under this paragraph.

(F) [inserted: Survey reporting.—] [inserted: In order to meet the requirement of section 1902(a)(54), a State shall require that any pharmacy in the State that receives any payment, reimbursement, administrative fee, discount, rebate, or other price concession related to the dispensing of a covered outpatient drug to an individual receiving benefits under this title, regardless of whether such payment, reimbursement, fee, discount, rebate, or other price concession is received directly from the State or a managed care entity or other specified entity (as such terms are defined in section 1903(m)(9)(D)), or is received indirectly from a pharmacy benefits manager or another entity that has a contract with the State or a managed care entity or other specified entity (as so defined)—]

(i) [inserted: shall respond to surveys conducted under this paragraph; and]

(ii) [inserted: shall include in each such response the pharmacy’s acquisition price for each such drug, net of all such payments, reimbursements, administrative fees, discounts, rebates, and other price concessions (or, in the case that the pharmacy is unable to determine the net acquisition cost for such a drug at the time that the survey is received, the pharmacy’s negotiated price for such drug).]

(G) [inserted: Survey information.—] [inserted: The Secretary shall make information on national drug acquisition prices obtained under this paragraph publicly available. Such information shall include at least the following:]

(i) [inserted: The monthly response rate to the survey, including a list of pharmacies not in compliance with subparagraph (F).]

(ii) [inserted: The sampling methodology and number of pharmacies sampled monthly.]

(iii) [inserted: Information on price concessions to each pharmacy, including discounts, rebates, and other price concessions, to the extent that such information is available during the survey period.]

(H) [inserted: Limitation on use of applicable non-retail pharmacy pricing information.—] [inserted: No State shall use pricing information reported by a pharmacy that is not a retail pharmacy to develop or inform reimbursement rates for retail community pharmacies.]

(2) Annual State report Each State shall annually report to the Secretary information on—

(A) the payment rates under the State plan under this subchapter for covered outpatient drugs;

§ 1396r–8(k)Definitions(10)–(14)

(f)(2)(B)–(k)(9) unchanged ·

(10) Retail community pharmacy The term “retail community pharmacy” means an independent pharmacy, a chain pharmacy, a supermarket pharmacy, or a mass merchandiser pharmacy that is licensed as a pharmacy by the State and that dispenses medications to the general public at retail prices. Such term does not include a pharmacy that dispenses prescription medications to patients primarily through the mail, nursing home pharmacies, long-term care facility pharmacies, hospital pharmacies, clinics, charitable or not-for-profit pharmacies, government pharmacies, or pharmacy benefit managers.

(11) Wholesaler The term “wholesaler” means a drug wholesaler that is engaged in wholesale distribution of prescription drugs to retail community pharmacies, including (but not limited to) repackers, distributors, own-label distributors, private-label distributors, jobbers, brokers, warehouses (including distributor’s warehouses, chain drug warehouses, and wholesale drug warehouses) independent wholesale drug traders, and retail community pharmacies that conduct wholesale distributions.

(13) [inserted: Pharmacy benefit manager; PBM.—] [inserted: The terms “pharmacy benefit manager” and “PBM” have the meaning given such terms in section 1860D–12(h)(C).]

(14) [inserted: Steering.—] [inserted: The term “steering” has the meaning given such term in section 1860D–12(h)(E), except that any reference in such section to the “PDP sponsor” is deemed a reference to a managed care entity or other specified entity (as such terms are defined in section 1903(m)(9)(D)) that is responsible for coverage of covered outpatient drugs, and any reference to a “covered part D drug” is deemed a reference to a covered outpatient drug.]

Step through the changes